Greg Cima

Articles Authored by Greg Cima
The firm said it has secured US Food and Drug Administration breakthrough device designation for its test to classify infections and stratify patients by severe disease risk.
The laboratory services spinoff of Nonacus is launching sales of a next-generation sequencing-based test that could help determine which patients need cystoscopies.

Hologic Non-COVID Fiscal Q4 Dx Revenues Rise 17 Percent
The firm reported that, excluding COVID-19 testing, its molecular diagnostics business grew 15 percent and overall diagnostics business grew 11 percent.
Siemens Healthineers Non-COVID Q4 Revenues up 11 Percent; CEO Addresses Rumors of IVD Business Sale
Company officials addressed rumors that the firm may be looking to sell its IVD business, as its CEO called such reports a "distraction."
Research teams report progress in identifying the biomarkers of psychiatric disorders, and one team aims to deliver tests for use with psychiatric evaluations.

DiaSorin Q3 Non-COVID-19 Revenues Rise 2 Percent, Collaborates With Gilead Sciences on HDV Assay
The firm reported its immunodiagnostics revenues rose on strong sales in Europe and North America while molecular instrument sales normalized from previous highs.
The firm is expanding its lab capabilities and leveraging its test development reputation to form partnerships early in the drug development process.
Revvity Q3 Revenues Drop 6 Percent on Weaker Pharma, Biotech Demand
The firm reported its diagnostics revenues were down about 9 percent, while its life sciences revenues dipped 2 percent.
The firm is using infrared spectroscopy to fill a testing need it discovered while developing a newer type of anticoagulant drug that has overtaken warfarin recently in popularity.

The UK-based firm plans to finish development in the coming year of multiplex lateral flow assays for detection of multiple diseases or management of single diseases.